IL1RN基因变异对全身型幼年特发性关节炎IL-1阻断治疗反应的影响
但发现从发病到诊断时间较长与较差的长期治疗反应相关。
要点
- 从发病到诊断时间较长者后续更可能接受托珠单抗治疗,提示诊断延迟与较差长期反应相关。
- 结果支持「机会窗口」假说,即缩短发病至诊断(及治疗)时间可能改善长期治疗反应。
核心结论
- 本研究未能证实在全身型JIA患者中IL1RN SNP对阿那白滞素或卡那单抗IL-1阻断治疗反应的影响。
- 从发病到诊断时间较长与较差的长期治疗反应相关,支持「机会窗口」假说。
研究设计与样本
- 分析7个报道与阿那白滞素治疗反应相关的IL1RN SNP中的6个,并评估人口学、病程、实验室数据及治疗反应。
- 治疗反应评估包括临床反应、是否换用抗IL-6受体治疗、6个月内达到临床非活动性疾病、改良幼年关节炎疾病活动评分改善及达到无糖皮质激素状态。
主要发现
- 6个IL1RN SNP以单倍型形式遗传,但未发现IL1RN单倍型或SNP与IL-1阻断治疗反应相关。
- 接受托珠单抗治疗者从发病到诊断的中位时间(0.27年)长于未接受托珠单抗者(0.08年)。
关键数值与推荐
- 共分析6个IL1RN SNP(报道与阿那白滞素治疗反应相关的7个SNP中的6个)。
- 接受托珠单抗者从发病到诊断中位时间0.27年,未接受者0.08年。
临床怎么用
- 对于全身型JIA患者,应尽早诊断并启动治疗,以争取改善长期治疗反应。
- IL1RN SNP检测目前不足以指导IL-1阻断治疗的选择。
局限性
- 仅分析了7个报道SNP中的6个,未覆盖全部已知变异。
- 为登记库队列研究,治疗反应评估方法多样,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the reported association of IL1RN polymorphisms with response to interleukin-1 (IL-1) blockade in a German cohort of patients with systemic juvenile idiopathic arthritis (JIA), and to assess the impact of other factors on treatment response. METHODS: Sixty-one patients with systemic JIA who had received IL-1 blockade were identified within the German Autoinflammatory Disease registry DNA biobank. Response to IL-1 blockade was assessed according to 1) the clinical response (initially at least a transient response or good response compared to a poor response), 2) switch (or no switch) to anti-IL-6 receptor therapy following IL-1 blockade, 3) achievement of clinically inactive disease within 6 months of IL-1 blockade, 4) improvement in disease activity measured using the modified Juvenile Arthritis Disease Activity Score, and 5) achievement of a glucocorticoid-free state. In addition, basic demographic data, key features of the disease course, laboratory data, and IL1RN single-nucleotide polymorphisms (SNPs) were assessed. RESULTS: Six of 7 IL1RN SNPs reported to be associated with response to anakinra therapy were analyzed. These 6 IL1RN SNPs were inherited as haplotypes. An association of IL1RN haplotypes and SNPs with response to IL-1 blockade could not be confirmed in this cohort of patients with systemic JIA. Patients who received tocilizumab following IL-1 blockade had a longer duration from disease onset to diagnosis than those who did not receive tocilizumab (median 0.27 years versus 0.08 years). CONCLUSION: The results of this study could not confirm an impact of IL1RN SNPs on response to IL-1 blockade therapy with either anakinra or canakinumab in a cohort of patients with systemic JIA. However, a longer time frame from disease onset to diagnosis was associated with poorer long-term treatment response, thereby supporting the "window of opportunity" hypothesis that suggests improved long-term treatment response with shorter time from disease onset to diagnosis (and treatment).
引用
- Hinze C, Fuehner S, Kessel C, et al. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2020. PMID: 31599092. doi:10.1002/art.41130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。